Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of the SGLT-2 Inhibitor Dapagliflozin on Impaired Awareness of Hypoglycemia in Type 1 Diabetes

NCT03556033 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT03556033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03556033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of the SGLT-2 Inhibitor Dapagliflozin on Impaired Awareness of Hypoglycemia in Type 1 Diabetes
Lead sponsor
Radboud University Medical Center
Phase
Phase 2
Overall status
Completed
Start date
November 23, 2018
Completion date
December 20, 2019
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 1, hypoglycemia, hypoglycemia unawareness